Safety and Efficacy Study of Sintilimab Combined With IBI305 in Patients With Advanced Hepatocellular Carcinoma
Status:
Completed
Trial end date:
2020-11-11
Target enrollment:
Participant gender:
Summary
This is a Phase Ib study to evaluate the safety, tolerability and efficacy of Sintilimab
combined with IBI305 in patients with advanced hepatocellular carcinoma in China.